Anixa Biosciences (ANIX) Corporate presentation summary

Business overview and financials

• Clinical-stage company focused on first-in-class cancer therapies and prevention products, with a robust pipeline and strong clinical data.

• Maintains a capital-efficient model, leveraging partnerships to minimize overhead and cash burn, with $15M in cash and no debt as of October 31, 2025.

• Consistent insider buying and a clean capital table, with 33M shares outstanding.

Clinical pipeline and partnerships

• Lead CAR-T program (Lira-cel) targets ovarian cancer, in partnership with Moffitt Cancer Center and The Wistar Institute, currently in Phase 1.

• Breast cancer vaccine program, licensed from Cleveland Clinic, completed Phase 1 and is entering Phase 2.

• Additional pre-clinical vaccine programs for ovarian, lung, colon, and prostate cancers, with collaborations involving Cleveland Clinic and NIH.

CAR-T technology and ovarian cancer program

• Lira-cel uses FSHR-mediated CAR-T technology, targeting a unique antigen found primarily on ovaries and tumor vasculature.

• Dual mechanism: direct tumor cell killing and anti-angiogenesis by destroying tumor blood vessels.

• Intraperitoneal delivery enhances tumor targeting and reduces systemic side effects.

• Dose-escalation Phase 1 trial ongoing in recurrent/chemoresistant ovarian cancer, with multiple cohorts and increasing cell doses.